Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

(University of Texas M. D. Anderson Cancer Center) The 3-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.